Pharmacogenomics of antipsychotic-induced weight gain: A systematic review
Schizophrenia Research · 2026
DOI: 10.1016/j.schres.2026.07.013 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Schizophrenia Research, 2026. Verfasst von Martin Kronenbuerger und 13 weiteren Autor:innen. Beteiligte Einrichtung: Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada;…. Hauptthemen laut MEDLINE: Antipsychotic Agents, Schizophrenia, Weight Gain. Die Arbeit nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Centre for Addiction and Mental Health, Canadian Institutes of Health Research.
Abstract (Originalsprache)
BACKGROUND: Antipsychotic-induced weight gain (AIWG) is a major clinical concern, affecting approximately 30% of patients. Clinical predictors explain only part of AIWG risk. Genetic and molecular variations are hypothesized to contribute to susceptibility. The purpose of this review is to summarize recent results to identify replicated and novel findings. STUDY DESIGN: Applying PRISMA guidelines, we searched MEDLINE, Embase, and PsycINFO (May 2018-May 2026) for studies on genetic and molecular associations with AIWG, extending our prior review. Reviews, editorials, and conference abstracts were excluded. We extracted study characteristics (design, diagnosis, antipsychotic exposure, sample size, ancestry, genetic variants, and AIWG outcomes) (e.g., ≥7% weight gain, BMI change). RESULTS: Fifty-three studies met inclusion criteria. In candidate gene studies, the most consistently replicated genes associated with AIWG were observed for DRD2, HTR2C, and MC4R. Multiple novel associations were identified by genome-wide association studies (GWAS) (e.g., MAP2K1, ZDBF2, PEPD), polygenic risk scores (PRS) (e.g., body mass index PRS), gene expression (e.g., CYP3A4, EP300), and epigenetic analyses (e.g., cg12034943 at CRTC1). CONCLUSIONS: Polymorphisms in candidate genes related to neurotransmission and appetite regulation continue to be investigated for associations with AIWG, while novel findings have emerged from GWAS, gene expression, and epigenetic studies. Evidence remains inconsistent due to limited replication, methodological variability, sparse ancestry data, and geographical underrepresentation. No single genetic variant is ready for clinical use, and multi-omic and multi-ancestry models are needed to improve prediction and clinical utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; University Hospital of Psychiatry and Psychotherapy, University of Be…
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Division of Clinical Research Education and Training & Public Relatio…
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada.
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Psychiatry, Faculty of Medicine, University of Ottawa,…
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Clinical Pharmacy and Pharmacy Practice, Faculty of Pha…
- Tanenbaum Centre for Pharmacogenetics, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Department of Pharmacology and Toxicology, University of Toronto, Tor…
Förderung
- Centre for Addiction and Mental Health
- Canadian Institutes of Health Research
Zitieren
APA
Kronenbuerger, M., Yoshida, K., Li, P. Y., Tavakoli, E., Magarbeh, L., Elsheikh, S. S. M., Gorbovskaya, I., Zai, C. C., Fleischmann, R., Zai, G., Kloiber, S., Kennedy, J. L., Müller, D. J., & Tiwari, A. K. (2026). Pharmacogenomics of antipsychotic-induced weight gain: A systematic review. Schizophrenia Research. https://doi.org/10.1016/j.schres.2026.07.013
Vancouver
Kronenbuerger M, Yoshida K, Li PY, Tavakoli E, Magarbeh L, Elsheikh SSM, et al. Pharmacogenomics of antipsychotic-induced weight gain: A systematic review. Schizophrenia Research. 2026. doi:10.1016/j.schres.2026.07.013
BibTeX
@article{Kronenbuerger2026,
author = {Kronenbuerger, Martin and Yoshida, Kazunari and Li, Pei Yuan and Tavakoli, Emytis and Magarbeh, Leen and Elsheikh, Samar S M and Gorbovskaya, Ilona and Zai, Clement C and Fleischmann, Robert and Zai, Gwyneth and Kloiber, Stefan and Kennedy, James L and Müller, Daniel J and Tiwari, Arun K},
title = {Pharmacogenomics of antipsychotic-induced weight gain: A systematic review},
journal = {Schizophrenia Research},
year = {2026},
doi = {10.1016/j.schres.2026.07.013}
}
EUVIMED